ALKEM

Alkem Laboratories Limited

Branded generics at home, with international formulations, biosimilars and devices

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

alkemlabs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹5050.00
Market cap
60,377 Cr
Stock P/E
28.0
P/B
4.37
Dividend yield
1.0%
ROE (FY26)
16.0%
ROCE (FY26)
19.0%
Operating margin (FY26)
17.8%
Debt / equity (FY26)
0.12
OCF / EBITDA (FY26)
65.3%
OCF / EBITDA (3Y)
75.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Alkem makes and sells branded generic medicines in India, with an international formulations business and a medical-device (MedTech) arm.

Company snapshot

12thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 16.0% — the business keeps a healthy share of every rupee it earns.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales3,440 Cr3,324 Cr2,936 Cr3,032 Cr3,415 Cr3,374 Cr3,144 Cr3,371 Cr4,001 Cr3,737 Cr3,603 Cr3,740 Cr
Operating expenses (approx.)2,693 Cr2,616 Cr2,534 Cr2,423 Cr2,662 Cr2,615 Cr2,752 Cr2,632 Cr3,080 Cr2,909 Cr3,086 Cr2,974 Cr
EBITDA747 Cr708 Cr402 Cr609 Cr753 Cr759 Cr391 Cr739 Cr921 Cr828 Cr517 Cr766 Cr
OPM %21.7%21.3%13.7%20.1%22.0%22.5%12.4%21.9%23.0%22.2%14.4%20.5%
Other income63 Cr94 Cr88 Cr120 Cr134 Cr93 Cr146 Cr136 Cr104 Cr143 Cr200 Cr153 Cr
Interest30 Cr25 Cr27 Cr29 Cr28 Cr36 Cr28 Cr30 Cr35 Cr42 Cr54 Cr47 Cr
Depreciation74 Cr70 Cr83 Cr80 Cr79 Cr85 Cr112 Cr88 Cr94 Cr95 Cr106 Cr100 Cr
Profit before tax648 Cr655 Cr367 Cr619 Cr780 Cr731 Cr396 Cr771 Cr895 Cr781 Cr422 Cr771 Cr
Tax %5.1%7.7%17.1%11.2%10.0%12.3%18.5%13.3%13.0%16.4%40.5%32.5%
Net profit615 Cr604 Cr304 Cr550 Cr702 Cr641 Cr322 Cr668 Cr779 Cr653 Cr251 Cr521 Cr
EPS (₹)₹51.90₹49.76₹24.55₹45.60₹57.60₹52.34₹25.57₹55.56₹63.99₹53.19₹19.77₹43.49

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5,853 Cr6,431 Cr7,357 Cr8,344 Cr8,865 Cr10,634 Cr11,599 Cr12,668 Cr12,965 Cr14,712 CrSign in free for the trailing twelve months
Operating expenses (approx.)4,854 Cr5,403 Cr6,242 Cr6,871 Cr6,923 Cr8,581 Cr9,990 Cr10,422 Cr10,452 Cr11,707 CrSign in free for the trailing twelve months
EBITDA999 Cr1,028 Cr1,115 Cr1,473 Cr1,942 Cr2,053 Cr1,609 Cr2,245 Cr2,512 Cr3,005 CrSign in free for the trailing twelve months
OPM %17.1%16.0%15.2%17.7%21.9%19.3%13.9%17.7%19.4%20.4%Sign in free for the trailing twelve months
Other income112 Cr96 Cr88 Cr104 Cr233 Cr163 Cr216 Cr311 Cr494 Cr583 CrSign in free for the trailing twelve months
Interest45 Cr55 Cr55 Cr65 Cr59 Cr52 Cr107 Cr112 Cr122 Cr161 CrSign in free for the trailing twelve months
Depreciation101 Cr143 Cr193 Cr253 Cr275 Cr304 Cr310 Cr299 Cr357 Cr382 CrSign in free for the trailing twelve months
Profit before tax965 Cr926 Cr955 Cr1,260 Cr1,842 Cr1,844 Cr1,305 Cr2,023 Cr2,526 Cr2,869 CrSign in free for the trailing twelve months
Tax %6.2%31.1%19.0%8.8%12.2%8.9%22.8%10.5%12.3%18.0%Sign in free for the trailing twelve months
Net profit905 Cr638 Cr774 Cr1,149 Cr1,618 Cr1,680 Cr1,007 Cr1,811 Cr2,215 Cr2,351 CrSign in free for the trailing twelve months
EPS (₹)₹74.61₹52.77₹63.61₹94.26₹132.57₹137.63₹82.31₹150.19₹181.11₹192.51Sign in free for the trailing twelve months
Dividend payout %————20.7%25.1%52.6%29.8%22.8%26.1%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital24 Cr24 Cr24 Cr24 Cr24 Cr24 Cr24 Cr24 Cr24 Cr24 Cr
Reserves4,444 Cr4,840 Cr5,415 Cr6,137 Cr7,353 Cr8,614 Cr9,021 Cr10,288 Cr11,961 Cr13,796 Cr
Borrowings654 Cr892 Cr903 Cr1,663 Cr1,670 Cr2,668 Cr1,397 Cr1,214 Cr1,063 Cr1,624 Cr
Other liabilities1,331 Cr1,788 Cr1,734 Cr1,972 Cr2,291 Cr2,554 Cr2,925 Cr3,647 Cr4,195 Cr4,901 Cr
Total liabilities6,568 Cr7,666 Cr8,208 Cr9,943 Cr11,519 Cr14,069 Cr13,757 Cr15,575 Cr17,691 Cr20,873 Cr
Fixed assets (net)1,394 Cr1,873 Cr2,106 Cr2,306 Cr2,234 Cr2,287 Cr2,065 Cr2,161 Cr2,064 Cr2,695 Cr
CWIP299 Cr381 Cr493 Cr363 Cr393 Cr339 Cr310 Cr148 Cr477 Cr138 Cr
Investments553 Cr444 Cr324 Cr261 Cr333 Cr371 Cr622 Cr484 Cr1,846 Cr1,869 Cr
Loans & advances——31 Cr28 Cr31 Cr20 Cr7 Cr9 Cr9 Cr7 Cr
Inventories1,206 Cr1,442 Cr1,500 Cr1,819 Cr2,312 Cr3,006 Cr2,608 Cr2,661 Cr2,922 Cr3,333 Cr
Trade receivables714 Cr1,081 Cr1,248 Cr1,649 Cr1,607 Cr1,885 Cr2,132 Cr2,253 Cr2,466 Cr2,979 Cr
Cash & bank167 Cr167 Cr249 Cr176 Cr174 Cr232 Cr274 Cr455 Cr304 Cr248 Cr
Other assets2,235 Cr2,278 Cr2,258 Cr3,341 Cr4,434 Cr5,929 Cr5,739 Cr7,403 Cr7,603 Cr9,604 Cr
Total assets6,568 Cr7,666 Cr8,208 Cr9,943 Cr11,519 Cr14,069 Cr13,757 Cr15,575 Cr17,691 Cr20,873 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity471 Cr276 Cr780 Cr585 Cr1,265 Cr1,111 Cr1,683 Cr1,948 Cr1,913 Cr1,963 Cr
Cash from investing-286 Cr-367 Cr-316 Cr-741 Cr-999 Cr-1,435 Cr113 Cr-1,009 Cr-1,299 Cr-1,667 Cr
Cash from financing-138 Cr85 Cr-379 Cr79 Cr-272 Cr380 Cr-1,761 Cr-1,145 Cr-811 Cr-503 Cr
Net cash flow47 Cr-7 Cr84 Cr-77 Cr-2 Cr58 Cr42 Cr-207 Cr-186 Cr-222 Cr
Free cash flow (OCF − Capex)-174 Cr-408 Cr250 Cr222 Cr1,070 Cr772 Cr1,450 Cr1,689 Cr1,237 Cr1,346 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %19.3%16.7%15.6%16.6%20.6%16.5%13.0%17.9%19.6%19.0%
ROE %19.5%12.8%13.6%17.9%21.0%18.6%10.4%16.8%17.4%16.0%
Debtor days44616272666567656974
Inventory days303335301311352339310295309340
Days payable186223193163163132139194195229
Cash conversion cycle161173170220255271239166184185
OCF / EBITDA %47.2%26.9%69.9%39.7%65.1%54.1%104.5%86.8%76.1%65.3%
OCF / EBITDA % (3 years)——48.6%45.4%58.0%54.1%72.4%80.3%87.1%75.0%
Debt / equity0.150.180.170.270.230.310.150.120.090.12
Current ratio1.731.641.921.691.921.762.322.612.732.55
Net debt / EBITDA0.49—0.591.010.771.190.700.340.300.46